엔케이맥스

Market position

The company positions itself as a specialist immune cell therapy business spanning immune diagnosis through treatment. Press coverage described it as a front-runner among NK cell therapy developers, in a field where several hundred NK cell therapy trials are registered globally but no product has yet been commercialized; management compared its technology favorably to Nasdaq-listed Fate Therapeutics.

Management attributes differentiation to the ability to expand NK cells ex vivo at high purity and high activity in large volumes, retention of cytotoxicity after cryopreservation in its allogeneic cells, ownership of both autologous and allogeneic NK therapy lines, in-house GMP facilities in Korea and the US, and an integrated portfolio linking immune diagnostics, supplements and therapeutics.

Technology

Core technology is ex vivo expansion of NK cells at high purity and high activity. Management stated that from roughly 2.5 million NK cells in 70cc of blood the platform can expand to about 6 billion NK cells at 99.19% purity, and that its allogeneic NK cells retain about 85% of tumor-killing capacity after freeze-thaw. The SuperNK platform underpins the autologous candidate SNK01 and the allogeneic candidate SNK02. The diagnostic side rests on the NK Vue kit, which measures NK cell activity from a small blood volume within 48 hours. NK365 is manufactured in GMP facilities holding FDA and ISO9001 certification.

Go-to-market

Clinical development of cell therapy candidates in Korea, the United States, Mexico and Japan, including collaborations with global pharmaceutical companies on combination trials; regulatory filings with Korea's MFDS, the US and Japan's Ministry of Health, Labour and Welfare; and direct commercialization of diagnostics, health functional foods and research reagents.

Cancer patients and, in the Alzheimer's program, neurodegenerative disease patients via clinical trials; individuals and clinics using NK cell activity testing for immune monitoring; consumers of immune-support health functional foods; and roughly 2,000 research institutions and global diagnostic reagent companies purchasing its research reagents.

Geography

Headquartered at 440 Changryong-daero, Yeongtong-gu, Suwon, Gyeonggi Province, South Korea. GMP manufacturing facilities in Korea and the United States, a US affiliate (NKMAX America), clinical activity in Korea, the United States and Mexico, and Japanese GMP authorization for NK cell therapy manufacturing. Research reagents are supplied to about 2,000 research institutions worldwide.

History

Founded in 2002 (incorporated 14 January 2002) and originally known as ATGen (에이티젠). A related company established in 2016 was merged into ATGen in February 2019, at which point the corporate name was changed to 엔케이맥스 (NKMAX). The company listed on the Korean market in 2018 under ticker 182400. In 2025 it renamed itself NKGen Biotech Korea (NK젠바이오텍코리아), described as the Korean entity of NKGen Biotech. Chairman/founder Park Sang-woo led the company as CEO; a change of representative director was disclosed in August 2025, with Kim Yong-man listed as CEO.

Risks & controversies

In March 2024 accumulated unfaithful-disclosure designations triggered a listing-eligibility substantive review and suspension of trading in the company's shares. The auditor, Taesung Accounting Corporation, issued a disclaimer of opinion on the most recent fiscal year's financial statements, raising delisting risk. Founder and then-CEO Park Sang-woo's stake fell to 0.01% after forced liquidation of share-collateralized loans by bondholders, and a vice president sold KRW 165.17m of stock on the market; shareholders voiced grievances at the March 2024 general meeting. Financial statements show sustained heavy losses, negative book value per share in 2023 (BPS -112.67) and declining revenue. The company remains classified as a KOSDAQ administrative issue.